Background: The efficacy of a novel inactivated intradermal Lawsonia intracellularis vaccine, Porcilis® Lawsonia ID, was evaluated in two experimental vaccination-challenge studies and under field conditions on a farm with a history of recurrent acute ileitis. In addition, the efficacy of the vaccine was compared to that of a commercially available live attenuated vaccine. The novel inactivated vaccine consists of a freeze-dried antigen fraction that is dissolved just prior to use in either the adjuvant or in Porcilis® PCV ID; an existing intradermal vaccine against porcine Circovirus type 2. In the two experimental vaccination-challenge studies, groups of 25 piglets were vaccinated once at 3 weeks of age or left unvaccinated as challenge control. Vaccines tested were Porcilis® Lawsonia ID as standalone (study 1) or in associated mixed use with Porcilis® PCV ID (study 2) and an orally administered commercially available live vaccine (study 1). The pigs were challenged with virulent L. intracellularis at 4 weeks (study 1) or 21 weeks (study 2) after vaccination. Post-challenge, the pigs were evaluated for clinical signs, average daily weight gain, shedding and macroscopic as well as microscopic immuno-histological ileum lesion scores. In the field study, the mortality and key performance parameters were evaluated over a period of 8 months. Results: The results of the two experimental vaccination-challenge studies showed that Porcilis® Lawsonia ID as single vaccine or in associated mixed use with Porcilis® PCV ID, induced statistically significant protection against experimental L. intracellularis infection, 4 weeks or 21 weeks after vaccination. This was demonstrated by lower clinical scores, improved weight gain, reduction of L. intracellularis shedding and reduction of macroscopic as well as microscopic ileum lesion scores when compared to the controls. The protection induced was superior to that of the commercially available live vaccine. In the field study Porcilis® Lawsonia ID was highly efficacious in reducing L. intracellularis associated mortality and improving key production parameters. Conclusion: The results support that this new intradermal vaccine is efficacious against L. intracellularis and may be used in associated mixed use with Porcilis® PCV ID.
Vaccination is an effective tool to limit equine influenza virus (EIV H3N8) infection, a contagious respiratory disease with potentially huge economic impact. The study assessed the effects of antigenic change on vaccine efficacy and the need for strain update. Horses were vaccinated (V1 and V2) with an ISCOMatrix-adjuvanted, whole inactivated virus vaccine (Equilis Prequenza, group 2, FC1 and European strains) or a carbomer-adjuvanted, modified vector vaccine (ProteqFlu, group 3, FC1 and FC2 HA genes). Serology (SRH, HI, VN), clinical signs and viral shedding were assessed in comparison to unvaccinated control horses. The hypothesis was that group 2 (no FC2 vaccine strain) would be less well protected than group 3 following experimental infection with a recent FC2 field strain (A/equi-2/Wexford/14) 4.5 months after vaccination. All vaccinated horses had antibody titres to FC1 and FC2. After challenge, serology increased more markedly in group 3 than in group 2. Vaccinated horses had significantly lower total clinical scores and viral shedding. Unexpectedly, viral RNA shedding was significantly lower in group 2 than in group 3. Vaccination induced protective antibody titres to FC1 and FC2 and reduced clinical signs and viral shedding. The two tested vaccines provided equivalent protection against a recent FC2 EIV field strain.
An objective of the present studies was to compare the protective effects of two European licensed canine tetravalent leptospirosis vaccines, Nobivac L4 and Versican Plus L4. Four similar challenge studies in beagle dogs were performed. In each study the dogs were assigned to one of three treatment groups as follows: group 1, Nobivac L4; group 2, Versican Plus L4; group 3, non-vaccinated control group. Two vaccinations were followed by a Leptospira challenge. Strains of the following serogroups were used for challenge: study 1, Grippotyphosa; study 2, Icterohaemorrhagiae; study 3, Canicola; study 4, Australis. Parameters of efficacy were antibody titres; body temperature; clinical signs; cultures of Leptospira bacteria from the blood, urine, kidney and liver; rapid urinalysis; macroscopic and histopathological examination at necropsy. It was concluded that compared to vaccination with Versican Plus L4, vaccination with Nobivac L4 resulted in generally better control of leptospirosis disease parameters after the challenge including a complete prevention of the clinical signs following a Grippotyphosa and Icterohaemorrhagiae challenge. In contrast, vaccination with Versican Plus L4 only prevented infection by Australis and shedding by Grippotyphosa and Australis but it did not lead to any statistically significant reduction of either infection or shedding following an Icterohaemorrhagiae challenge.
11 February 2025 in Research in Veterinary Science
To approve veterinary medicines, regulatory agencies require substantial evidence of safety and effectiveness from well-designed trials. A critical consideration in planning a veterinary trial is to determine the requisite number of subjects needed to achieve the trial objective(s). Sample sizes for preclinical studies usually follow specific guidelines, whereas clinical studies should follow more rigorous requirements to determine the optimal sample size for detecting significant and meaningful treatment effects. This paper presents a descriptive literature review aiming to explore current reported practices in sample size calculation for published veterinary clinical trials. The review included articles published in 12 top-ranking veterinary health journals from January 1, 2013, to June 4, 2023, sourced from PubMed and Medline regarding animal trials. Initially, 294 articles were identified, of which 98 (33 %) focused on veterinary clinical studies. Among these 98 papers, only 24 (24 %) provided detailed methods on sample size calculations, with individual animals as experimental units across at least two arms. The predominant animal species studied in these trials were canines (39 %), cattle (32 %), and swine (21 %), with most studies aiming for a statistical power of at least 80 %. Unlike human clinical trials, the paper found that statistically rigorous sample size calculations were less commonly reported in animal clinical trials. Our paper provides recommendations for veterinary clinical trial practitioners and offers insights into how sample size determination can be properly conducted and reported. Furthermore, this article extends to discuss practical issues in sample size determination for preclinical studies.
Background/Objectives: Typically, studies aiming to assess the ability of canine parvovirus (CPV) vaccines to immunise puppies with maternally derived antibody (MDA) are undertaken using group-housed puppies. Since live attenuated vaccine virus is invariably shed in the faeces, this can result in repeated oral re-exposure and puppies which failed to respond to the initial vaccination may respond instead to shed vaccine virus in the environment, thus artificially enhancing the efficacy of the vaccine. This problem can be avoided by adopting a pair-housed study design where one vaccinated pup is housed with one unvaccinated sentinel. Using this design, we examine the capability of four commercially available canine parvovirus vaccines to immunise MDA-positive pups. Methods: Thirty-four 6-week-old puppies born to vaccinated dams were divided into four vaccine groups with similar MDA ranges. Within each group puppies were paired based on matching MDA titres, and each pair was housed in separate biocontainment accommodation. In each pair, the pup with the highest MDA was vaccinated and the other left as an unvaccinated sentinel. All vaccinates were given a single dose of one of the vaccines. Vaccinates and sentinels were then bled every 2–4 days and CPV antibody was measured. Daily rectal swabs were also collected from all pups to identify any shed vaccinal CPV. Results: All the pups vaccinated with Nobivac DP PLUS seroconverted, with significantly higher antibody titres compared to the pups in other vaccine groups, all shed vaccine virus, and all bar one of the sentinel pups seroconverted. In the other groups, only vaccinated pups with lower levels of MDA seroconverted and shed vaccine virus but none of the sentinel pups seroconverted. Conclusions: Different canine parvovirus vaccines differ in their ability to replicate in and immunise puppies with MDA, the levels of which may vary widely between individuals. The shedding of vaccinal CPV is an important consideration when designing studies to demonstrate efficacy in MDA-positive puppies.
Background/Objectives: Porcine Circovirus Type 2 (PCV2) and Mycoplasma hyopneumoniae are primary pathogens causing respiratory disease in pigs. Recently, a Ready-to-Use bivalent PCV2 and M. hyopneumoniae vaccine has been registered in China. The aim of this randomized, side-by-side trial was to evaluate the efficacy and safety of this vaccine under field conditions in a Chinese commercial pig farm. Methods: In total, 938 piglets were allocated to three groups—A (tested vaccine), B, C—and vaccinated according to different schemes. Efficacy was assessed by Average Daily Gain (ADG), pneumonia lesions at slaughter and PCV2 viremia. Systemic reactions were recorded after vaccination to evaluate safety. Results: ADG was higher in group A compared with other vaccination schemes. The prevalence of pneumonia lesions was significantly lower in group A. PCV2 viremia was overall low in all groups, with no reported differences. No severe or moderate systemic reactions were observed after vaccination. Only four pigs showed mild reactions (A: 2/320, B: 2/309; C: 0/309). Conclusions: Under these conditions, the tested vaccine was proved to be efficacious in increasing ADG and reducing pneumonia at slaughter by protecting against both PCV2 and M. hyopneumoniae field infections. It can also be concluded that the Ready-To-Use bivalent vaccine was safe.